MapLight Therapeutics financials
$10.15−2.87%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — |
| Operating income | -$63.5M | -$64.5M | -$83.4M |
| Net income | -$60.2M | -$60.7M | -$79.5M |
| Net margin | — | — | — |
| Diluted EPS | $-1.32 | $-1.34 | $-2.45 |
| EBITDA | -$63.4M | -$64.3M | -$83.2M |
| Operating cash flow | -$44.9M | -$51.2M | -$46.8M |
| Free cash flow | -$44.9M | -$51.2M | -$47.2M |
| Diluted shares | 45.4M | 45.3M | 32.4M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 |
|---|---|---|---|
| Cash & equivalents | $71.6M | $55.7M | $46.7M |
| Short-term investments | $233.1M | $254.4M | $258.4M |
| Total debt | $0.00 | $0.00 | $0.00 |
| Total assets | $368.3M | $418.8M | $479.5M |
| Total liabilities | $20.0M | $19.0M | $21.1M |
| Shareholders' equity | $348.3M | $399.8M | $458.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology